Germ-line mutations of the BRCA1 and BRCA2 genes, when they lead to a truncated protein, confer a high risk of breast and ovarian cancer. However, the role of BRCA1 missense mutations in cancer predisposition is unclear. Functional assays may be very helpful to more clearly define the biological effect of these mutations, and could therefore be useful in clinical practice. A recent study using a Host Cell End-Joining assay showed that a truncating mutation results in impaired fidelity of DSB repair by DNA end-joining. In the present study, we examined the fidelity of DSB repair in four lymphoblastoid cell lines with BRCA1 missense mutations. The fidelity of DNA end-joining was impaired in the four cell lines studied compared to the normal control cell line. The fidelity of end-joining was similar to that of a truncated mutation control cell line for one cell line and slightly higher for the other cell lines.
Introduction
Heterozygous germ-line mutations of the BRCA1 and BRCA2 genes confer a high risk of breast and ovarian cancer (Miki et al., 1994; Wooster et al., 1995) . According to the Breast Cancer Information Core (BIC) database, in February 2003, 1152 different BRCA1 mutations (excluding polymorphisms) have been identified in patients with a high probability of carrying BRCA1 mutation genes due to their personal and familial medical history. In all, 706 (61%) of these mutations led to truncated products and were therefore clearly associated with a deleterious protein effect. The remaining mutations consisted of 430 (37%) missense mutations and 16 (1%) inframe nucleotide mutations, generally leading to proteins with an unknown biological significance. The deleterious effect of these mutations is suggested when the following features are present: low mutation frequency in the general population; family mutation cosegregation with disease, and, for missense mutations, lack of similarity between the initial wildtype (wt) and mutant amino acid (aa); no phylogenetic amino-acid conservation; and location in putative functional domains. However, all these features are not generally sufficient to associate a given missense mutation with a deleterious effect. Functional assays may be very helpful to more clearly define the biological effect of these mutations, and could therefore be useful in clinical practice.
The human BRCA1 gene encodes a 1863 amino-acid nuclear protein (220 kDa). BRCA1 contains two known functional domains located in the N-and C-terminal regions which are highly conserved: one RING finger domain (24-64 aa), two BRCT domains (BRCA1 C-terminus) (1649-1736, 1756-1855 aa) (Koonin et al., 1996) . BRCT domains are present in many proteins involved in DNA repair, but their biological functions are still unclear (Huyton et al., 2000) . BRCA1 interacts directly or indirectly with numerous proteins involved in various cellular pathways: transcriptional regulation, cell cycle/checkpoint control, protein ubiquitination, chromatin remodelling, and DNA repair (see Venkitaraman (2002) for review).
BRCA1 appears to play an important role in DNA damage, since human tumour cells lacking BRCA1 and mouse embryonic Brca1À/À fibroblasts (MEF) are highly sensitive to ionizing radiation (IR) (Shen et al., 1998; Foray et al., 1999; Scully et al., 1999) . The most deleterious DNA damage induced by IR are doublestrand breaks (DSB) which are repaired in eukaryotes by two major pathways: homologous recombination (HR) and DNA end-joining (EJ) (see Khanna and Jackson, 2001 , for review). BRCA1 is involved in HR, as it colocalizes with RAD51, a HR key protein, in IR-induced nuclear foci in mitotic cells (Scully et al., 1997; Chen et al., 1999) . It is also detected with RAD51 in synaptonemal complexes in meiotic cells (Scully et al., 1997; Chen et al., 1999) . In addition, decreased HR has been observed in Brca1À/À embryonic stem cells using an unique DSB introduced into a chromosomal recombination substrate (Moynahan et al., 1999) . However, BRCA1 also appears to be involved in EJ, as it interacts in vitro and in vivo with the RAD50/ MRE11/NBS1 complex, which is thought to play a role in both HR and EJ (Zhong et al., 1999) . Moreover, recent studies provide strong evidence that the EJ pathway is impaired, in vivo and in vitro, in Brca1-/-MEF cells (Zhong et al., 2002a, b) . It has also been shown, in lymphoblastoid cell lines established from women carrying a truncating BRCA1 mutation, that the fidelity of EJ is severely decreased in vitro and in vivo (Baldeyron et al., 2002) . Additionally, BRCA1 þ /À cells, derived from breast cancer predisposed women, present an enhanced radiosensitivity, as observed after irradiation in lymphoblastoid cell lines by pulse field gel electrophoresis, in circulating blood lymphocytes by micronucleus analysis or chromatid break assay, and in fibroblasts by analysing cell survival (Foray et al., 1999; Rothfuss et al., 2000; Buchholz et al., 2002) .
In the present study, we used a functional Host Cell End-Joining assay (HCEJ) to examine the fidelity of DSB rejoining in an attempt to more clearly define the biological effect of four BRCA1 missense mutations.
Four lymphoblastoid cell lines harbouring a BRCA1 heterozygous missense mutation were derived from women with breast or ovarian cancer recruited from the Institut Curie family cancer clinic. These four patients presented a high probability of a genetic predisposition to breast and ovarian cancer (p (predisposition to be gene carrier)>77%) ( Table 1 ). Both BRCA1 and BRCA2 genes were analysed, with their informed consent, for point mutations by DGGE or DHPLC (Stoppa-Lyonnet et al., 1997; Wagner et al., 1999) , and for large BRCA1 rearrangements by colour bar code or QMPSF (quantitative multiplex PCR of short fluorescent fragments) (Casilli et al., 2002) . No mutations were detected apart from BRCA1 missense mutations. These mutations, whose characteristics are shown in Table 1 , were therefore candidates for being associated with partial or complete loss of BRCA1 function and corresponded to: K56R (cell line IC52) located in the RING finger; Q575 K (cell line IC954) located in the RAD50 interacting region; L1404R (cell line IC441) located in the ATM interaction region; and N1692 H (cell line IC692) located in the first BRCT domain.
Using the HCEJ assay, we analysed the recircularization in human cells of an extrachromosomal plasmid carrying a defined DSB. Two types of DSB were studied: blunt-ended (created by single EcoRV digestion), or a DSB with dissimilar ends (double-digestion EcoRV/ SalI). After 48 h of a transient transfection, the substrates repaired within the human cells were isolated. As shown in Figure 1 , the PvuII restriction profiles of recombinants were analysed first, followed by a second step analysis -either by EcoRV digestion (EcoRVinduced DSB) or by sequencing of plasmids with PvuII profiles similar to wt substrates (EcoRV/SalI-induced Two sisters, one with breast and ovarian cancer at the age of 43 and 51 years, respectively, and the other with ovarian cancer at the age of 47 years, both carried the 1404R mutation Fidelity of DNA double-strand break repair I Coupier et al Figure 1 Host cell end-joining assay (HCEJ). (a) Cell transfection and plasmid DNA extraction. Exponentially growing lymphoblastoid cells (8-10 Â 10 6 cells per experimental point) were electroporated with EcoRV or EcoRV/SalI linearized pHRecCJ plasmid (6.2 kb) (described in Escarceller et al., 1998) . The transfected cells were incubated at 371C for 48 h. Plasmid DNA was extracted by alkaline lysis procedure (Qiaprep s Spins, Qiagen). Only plasmids repaired and replicated in human cells were selected for further analysis. Nonrepaired plasmids were eliminated by digestion with DpnI, an enzyme which specifically recognizes and cleaves bacterially methylated GATC sites, leading to degradation of the remaining unrepaired linearized plasmids. After dialysis against distilled water, plasmid DNA was electroporated into XL1-blue competent E. coli (Stratagene, CA, USA) and plated onto LB agar plates containing ampicillin. Small-scale plasmid DNA samples were prepared from ampicillin-resistant bacterial colonies. (b) Analysis of rejoined plasmids. Two-step analysis was used to determine the fidelity of the EJ reaction: (1) PvuII digestion, which leads to five DNA fragments (2848, 2007, 593, 459, 324 bp) for the wt pHRecCJ plasmid. The error-free rejoined plasmids (EcoRV-induced DSB) or those containing few base pair deletions presented the same restriction profile as the wt pHRecCJ. The error-free rejoined plasmids (EcoRV/SalI-induced DSB) led to a similar digestion pattern, except for the shortest 324 bp fragment substituted by a 260 bp fragment due to a 64 bp deletion induced by the double digestion. (2) Plasmid DNAs with similar digestion patterns to those of wt PvuII were further analysed by either EcoRV digestion (2a) or sequencing of the 300 bp region surrounding the EcoRV and SalI restriction sites (2b). The R1 reverse primer (5 0 CAGGAAACAGCTATGACCATGA 3 0 ) was used and sequencing was performed on ABI 3100 PE (Applied Biosystems). Sequence Navigator software (Applied Biosystems) was used for analysis. The data represent the observed values from two to five independent experiments. The fidelity of EJ was calculated as a ratio of the number of accurately repaired plasmids over the total number of plasmids analysed (Tables 2 and 3) Fidelity of DNA double-strand break repair I Coupier et al DSB). The normal control cell line AHH1 was derived from a healthy individual, while the truncated mutation control cell line IC568 was obtained from a woman carrying a BRCA1 23.8 kb deletion encompassing exons 8-13 (Baldeyron et al., 2002) . The fidelity of DNA EJ was impaired in the four cell lines studied compared to the normal control AHH1 for both blunt ends and no complementary ends (Tables 2,  3) , as the rate of accurately rejoined plasmids in the AHH1 normal control was 37% (95% CI: 30.0-44.4%) and 27% (95% CI: 21.6-33.9%) for EcoRV-and EcoRV/SalI-induced DSB, respectively. In contrast, the proportion of accurately rejoined plasmids in the four cell lines harbouring BRCA1 missense mutations ranged between 3 and 15% and 5 and 12% for EcoRVand EcoRV/SalI-induced DSB, respectively (Tables 2, 3 ). The decreased fidelity of EJ for EcoRV-induced DSB in cell lines IC441 and IC692 was similar to that observed in the mutated control (IC568). However, the fidelity of EJ in cell lines IC52 and IC954 was slightly higher than in IC568 (Table 2) , while the fidelity of EJ of EcoRV/SalIinduced DSB in cell lines IC954 and IC441 was similar to that observed in IC568 (Table 3 ). The IC441 cell line was therefore the only cell line presenting similar results to those obtained for the heterozygous cell line carrying a truncated mutation for the two types of DSB.
The four cell lines studied presented a decreased fidelity of EJ repair compared to the normal control AHH1. The proportion of accurately rejoined plasmids in the AHH1 cell line was consistent with that observed in a second control cell line, HSC93, studied by Baldeyron et al. (2002) , adding further support to our finding. Indeed, fidelity rates in AHH1 and HSC93 cell lines were, respectively, 37 and 31% for EcoRV digestion (this study and Baldeyron et al., 2002) , 27 and 30% for EcoRV SalI digestion (this study and Baldeyron et al., unpublished data) . The fidelity of EJ of the four cell lines studied, except for IC441, harbouring the R1404 allele, which behaved like truncated mutation control cell line IC568 carrying a 23.8 kb BRCA1 deletion, appeared to be only slightly impaired compared to IC568 cells. The effect of missense mutations on the fidelity of EJ therefore appears to be attenuated compared to the effect of a truncated mutation. This may reflect the intermediate DNA repair capacities of the missense mutations tested, as the fidelity of EJ of IC52, IC954, and IC692 cell lines was still slightly higher than that observed for the two additional cell lines harbouring different BRCA1 truncating mutations (IC347, IC1549) studied by Baldeyron et al. Assuming that there is a link between fidelity of EJ and breast cancer risk, such missense mutations would be expected to be associated with a lower cancer risk compared to truncated mutations. Attenuated phenotypes associated with missense mutations have already been described, for instance in ataxia-telangiectasia (Stankovic et al., 1998) . R56 and H1692 mutations are located in highly phylogenetically conserved protein domains. In addition, the 5193G>C base substitution associated with the N1692H amino-acid change is located on the last nucleotide of exon 17. Although no abnormal transcript was detected in patient leucocytes 
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184 (5) 212 (5) 260 (5) 216 (2) 126 (2) 123 (3) Number of plasmids accurately rejoined 68 (37%) (30-44.4%) 6 (3%) (1.05-6.1%) 24 (9%) (6-13.4%) 32 (15%) (10.4-20.3%) 4 (3%) (0.9-7.9%) 8 (6.5%) (2.8-12.4%)
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The significance of the difference in fidelity of DNA repair between cell lines harbouring a missense mutation and the normal control (AHH1) or mutated control (IC568) was determined by the w 2 test or Fisher test ( * ). 95% exact confidence intervals of the fidelity rates obtained from all of the independent experiments are given in parentheses
Fidelity of DNA double-strand break repair I Coupier et al or in the derived lymphoblastoid cell line, a possible splicing defect leading to a truncating mutation cannot be excluded. A decreased fidelity of repair was therefore not unexpected in these two cell lines. However, we cannot immediately conclude that the decreased fidelity of EJ observed in a given cell line is linked to a BRCA1 missense mutation, as the HCEJ assay is not genespecific, since it analyses the EJ DNA repair pathway and none of its specific components. Indeed, there are only a few arguments in favour of a causal effect of the K575 mutation (IC954 cell line) and a normal repair capacity was expected. Q575 is an amino-acid conserved in mammals, but not located in a conserved region and it would not be associated with a deleterious effect according to Fleming's model, a model based on Bayesian phylogenetic analyses (Fleming et al., 2003) . In addition, a lack of cosegregation with breast cancer was observed in the family, as the patient's sister, affected with breast cancer, did not present the K575 mutation. This decreased fidelity of repair observed in the IC954 cell line could be related to an unidentified BRCA mutation or to mutations of other genes involved in DNA repair, as suggested by the observation of cosegregation between cellular radiosensitivity and breast cancer in some families (Roberts et al., 1999) . In a previous study, it was shown by immunoblot analysis that the quantity of the wild-type BRCA1 protein was significantly lower than the 50% expected for heterozygous cells carrying a nonsense or a frameshift mutation (Baldeyron et al., 2002) . Since it was interesting to do similar experiments in these cell lines carrying a BRCA1 missense mutation, some preliminary experiments were done. The results, although showing a decrease of BRCA1 protein (data not shown), need to be confirmed.
At the present time, the HCEJ assay, by determining the capacity of cells to perform faithful DNA EJ, may be useful to better characterize the deleterious effect of missense BRCA1 mutation. However, to confirm that the observed defect is BRCA1-specific, it would be useful to determine whether the phenotype can be complemented with wt BRCA1, although correction of the phenotype is not specific for a given mutation and the presence of another, undetected BRCA1 mutation cannot be excluded. In order to definitively link these missense mutations with a breast cancer risk, the BRCA1 missense mutation would need to be introduced into a normal control cell line by directed mutagenesis, but this would be very difficult to perform in human cells. Consequently, although the HCEJ assay appears to be useful, an additional assay would be necessary to definitively link a BRCA1 missense mutation with cancer predisposition. However, despite the point cautiously discussed above, the observed decreased EJ repair fidelity brings additional arguments for a causal effect on breast and ovarian cancer predisposition of these BRCA1 missense mutations. 215 (4) 204 (4) 258 (5) 212 (2) 175 (3) 138 (3) Number of plasmids accurately rejoined 59 (27%) (21.6-33.9%) 12(6%) (3.1-10.05%) 31 (12%) (8.3-16.6%) 10 (5%) (2.3-8.5%) 18 (10%) (6.2-15.8%) 17 (12%) (7.3-19%) Statistical analysis/normal control (AHH1)
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The significance of the difference in fidelity of DNA repair between cell lines harbouring a missense mutation and the normal control (AHH1) or mutated control (IC568) was determined by the w 2 test. 95% exact confidence intervals of the fidelity rates obtained from all of the independent experiments are given in parentheses 
